Belite Bio (NASDAQ:BLTE – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02), Zacks reports.
Belite Bio Price Performance
Belite Bio stock opened at $67.44 on Monday. The firm has a market cap of $2.15 billion, a PE ratio of -60.76 and a beta of -1.54. The stock’s fifty day moving average price is $58.40 and its two-hundred day moving average price is $60.33. Belite Bio has a one year low of $31.01 and a one year high of $86.53.
Wall Street Analyst Weigh In
Separately, Benchmark upped their price target on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Read More
- Five stocks we like better than Belite Bio
- Why Invest in High-Yield Dividend Stocks?
- Adobe Earnings Are In: Should You Buy, Sell, or Hold Now?
- What is a Bond Market Holiday? How to Invest and Trade
- Maximize Your Dividends With These 3 High-Yield ETFs
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Undervalued Stocks Poised for a Strong Comeback
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
